Mentor Capital, Inc. (OTC Markets: MNTR) announced

Mentor Capital, Inc. (OTC Markets: MNTR) announced it hasexecuted a Letter of Intent with Nanovega, Inc. for $6 Million to fund theproduction scale up of its ultra-small synthetic antibodies. These nano-scalemolecules are approximately one-tenth the size of most alternative cancerdelivery bio-markers.  The small sizeallows the nano-bodies to slip throughout solid tumors instead piling up at thesurface as is often currently encountered in cancer treatment. Marek Malecki, MD, PhD, President of Nanovega Inc., looksahead, “We are enthusiastic about the financial support provided by MentorCapital. With intellectual property protected [9 patents and applications] we look to scale up production of ourunique synthetic antibodies.”  Thenano-bodies are already produced for use by outside researchers and designedfor multiple diagnostic and therapeutic applications.  Mentor Capital CEO, Chester Billingsley, adds, “We areespecially intrigued by Nanovega’s ability to tag cancer cells or fragmentscirculating in the blood with ultra-small metal atoms.”  The metal nano-tags allow the cancer cells tobe separated out using a magnetic field. The separated cancer cells may then be quickly grown and tested outsidethe body to pre-determine the most effective chemotherapy to prescribe.    About Mentor Capital:  By acquisition or stock purchase, MentorCapital, Inc. seeks to invest in leading companies that reduce the cost ofmedical treatments especially in the fight against cancer. Additional importantinformation is presented at:  www.MentorCapital.comForward Looking Statements, Safe Harbor and RiskDescriptions are Incorporated by Reference from the MNTR Company Web Siteabove. For further information contact: Chester Billingsley, CEO                    Mentor Capital, Inc. (760) 788 - 4700 

test